Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
The Journal of Experimental Medicine|February 11, 2004
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapyKazuyoshi Takeda, Noriko Yamaguchi, Hisaya Akiba, et al.Phytochemistry|May 19, 2018
Cytotoxic and other withanolides from aeroponically grown Physalis philadelphicaYa-Ming Xu, E M Kithsiri Wijeratne, Alan D Brooks, et al.Blood|March 15, 2003
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIPThomas J Sayers, Alan D Brooks, Crystal Y Koh, et al.Journal of Biomolecular Screening|August 29, 2012
A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cellsLesley A Mathews, Jonathan M Keller, Bonnie L Goodwin, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2006
NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector functionKaren Abdool, Erika Cretney, Alan D Brooks, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 4, 2006
Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumorsTahira Khan, Jimmy K Stauffer, Rebecca Williams, et al.Journal of Natural Products|June 16, 2017
Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma CellsYa-Ming Xu, E M Kithsiri Wijeratne, Ashley L Babyak, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 21, 2003
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responsesWilliam J Murphy, Lisbeth Welniak, Timothy Back, et al.BMC Cancer|October 11, 2014
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcomaRobert J Canter, Erik Ames, Stephanie Mac, et al.Cancer Research|October 24, 2015
Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL CytotoxicityAnil Shanker, Samuel T Pellom, Duafalia F Dudimah, et al.Pageof 5